Exelixis, a prominent pharmaceutical company, has reported its financial performance for the second quarter of 2026, marking a pivotal period in its evolution toward a diversified oncology portfolio. The company's total revenues reached $628.7 million, representing a notable 10.6% increase from the previous year. This growth was largely propelled by strong sales of cabozantinib, which generated $573.0 million in net product revenues, reflecting a 10.2% year-over-year increase primarily due to higher sales volumes. The global cabozantinib franchise, including contributions from international partners, achieved $806 million, a 13% rise from the prior year. Despite this robust performance, the company adjusted its full-year 2026 total revenue guidance slightly downward to between $2.500 billion and $2.550 billion, primarily to account for a more gradual market penetration in the neuroendocrine tumor (NET) indication. Non-GAAP net income stood at $237.1 million, or $0.91 per diluted share, after excluding stock-based compensation and related tax effects.
The company's strategic focus is now centered on expanding its pipeline with zanzalintinib, a next-generation tyrosine kinase inhibitor, as it transitions from a single-compound entity to a multi-franchise oncology leader. Zanzalintinib is currently undergoing review for approval in third-line plus colorectal cancer, with a PDUFA date set for December 3, 2026, and is the subject of seven ongoing or imminent pivotal trials across various tumor types, including kidney cancer, bladder cancer, and prostate cancer. Notably, the STELLAR-304 study, evaluating zanzalintinib in non-clear cell renal cell carcinoma, completed enrollment last year and is expected to yield top-line results in the latter half of 2026, potentially establishing a new standard of care in an underserved patient population. Exelixis is also committed to disciplined capital allocation, demonstrated by the completion of a significant stock repurchase program and a reduction in its R&D expense guidance to maintain financial flexibility and maximize shareholder value. The company repurchased approximately $311.6 million worth of shares, retiring 6.5 million shares at an average price of $47.85.
Exelixis continues to demonstrate a strong commitment to addressing unmet needs in oncology by strategically advancing its product pipeline and expanding market reach. The successful development and commercialization of new therapies like zanzalintinib, alongside the sustained performance of cabozantinib, underscores the company's dedication to improving patient outcomes. This proactive approach to research, development, and market strategy not only strengthens its commercial position but also ensures long-term value creation for stakeholders and a brighter future for cancer patients worldwide. The relentless pursuit of innovative solutions and responsible financial stewardship exemplifies a company striving for excellence and positive impact.
